Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

2 Aug 2022

Abstract excerpt

Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. We found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35917568
DOI: 10.1182/bloodadvances.2022007875

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myelomaPMID 35917568Read ↗

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myelomaSemantic proximity Read ↗

SUMOylation Inhibition Enhances Dexamethasone Sensitivity in Multiple MyelomaSemantic proximity Read ↗

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomideSemantic proximity Read ↗

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.Semantic proximity Read ↗

Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic OpportunitiesSemantic proximity Read ↗

Therapeutic Potential of Targeting the SUMO Pathway in CancerSemantic proximity Read ↗

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read ↗

Lysin (K)-Specific Demethylase 1 Inhibition Enhances Proteasome Inhibitor Response and Overcomes Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.Semantic proximity Read ↗

Therapeutic Potential of PRMT1 as a Critical Survival Dependency Target in Multiple MyelomaSemantic proximity Read ↗

Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.